Z.A. AFANASIEVA^1,2, A.V. GALEEVA³, М.R. SHAIDULLINA^3,4, G.Sh. IMINOV^1,2

¹Kazan State Medical Academy — Branch Campus of  RMACPE MH Russia, Kazan

²Tatarstan Cancer Center, Kazan

³Children’s Republic Clinical Hospital of the MH of RT, Kazan

⁴Kazan State Medical University, Kazan

Contact:

Afanasieva Z.A. ―MD, Professor of the Oncology, Radiology and Palliative Medicine Department, Head of the Center for the diagnosis and treatment of patients with thyroid and other endocrine organs tumors

Address: 36 Butlerov Str., Kazan, Russian Federation, 420012, e-mail: z-afanasieva@mail.ru

Objective ― to systematize the modern data on multiple endocrine neoplasia syndrome, type 2B (MEN 2B).

Conclusion. The presented clinical observations demonstrate that children’s endocrinologists, pediatricians, and endocrinologist must be wary about MEN 2B syndrome. It may facilitate early diagnostics, timely treatment and improve prognosis in general.

Key words: multiple endocrine neoplasia syndrome (MEN), type 2B, thyroid medullar cancer, pheochromocytoma.

(For citation: Afanasieva Z.A., Galeeva A.V.,  Shaidullina М.R., Iminov G.Sh. Multiple endocrinal neoplasia, 2 В type. Clinical cases. Practical medicine. 2019. Vol. 17, № 5, P. 169-172)

REFERENCES

1. Kuznetsov N.S., Bel’tsevich D.G., Polyakova E.Yu. et al. Diagnosis and treatment of multiple endocrine neoplasia syndrome type 2. Khirurgiya, 2002, no. 2, pp. 4-9 (in Russ.).
2. Pinskiy S.B., Beloborodov V.A., Dvornichenko V.V. Mnozhestvennye endokrinnye neoplazii [Multiple endocrine neoplasias]. Novosibirsk: Nauka, 2012.
3. Rumyantsev P.O., Il’in A.A., Rumyantseva U.V. et al. New approaches to the diagnosis and treatment of hereditary forms of medullary thyroid cancer. Rossiyskiy onkologicheskiy zhurnal, 2007, no. 4, pp. 4-7 (in Russ.).
4. Rumyantsev P.O., Il’in A.A., Rumyantseva U.V., Saenko V.A. Rak shchitovidnoy zhelezy [Thyroid cancer]. Moscow: GEOTAR-Media, 2009. Pp. 110-121.
5. Ferreira C.V., Siqueira D.R., Ceolin L., Maia A.L. Advanced medullary thyroid cancer: pathophysiology and management. Cancer Manag. Res., 2013, May 8, 5, pp. 57-66 [PubMed].
6. Raue F., Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens), 2009, 8, pp. 23-28 [PubMed].
7. Yip L., Cote G.J., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch. Surg, 2003, 138, pp. 409-416 [PubMed].
8. Diagnosis and treatment of medullary thyroid cancer (Draft national clinical guidelines). Endokrinnaya khirurgiya, 2012, no. 1, pp. 5-17 (in Russ.).
9. Kazubskaya T.P., Kozlova V.M., Amosenko F.A. et al. Modern approaches in the treatment of medullary thyroid cancer. Vestnik RONTs im. N.N. Blokhina RAMN, 2011, vol. 22, no. 3, pp. 64-69 (in Russ.).
10. Gagel R., Marx J. Multiple endocrine neoplasia. Williams Textbook of Endocrinology. Sundery. Philadelf, 2008. Pp. 1705-1734.
11. Bel’tsevich D.G., Gerasimenko O.A., Fadeev V.V. et al. Based on the materials of clinical recommendations of the American thyroid association for medullary thyroid cancer. Klinicheskaya i eksperimental’naya tireoidologiya, 2009, vol. 5, no. 3, pp. 3-36 (in Russ.).
12. Gazizova D.O., Bel’tsevich D.G. A modern view of the problem of diagnosis and treatment of medullary thyroid cancer. Endokrinnaya khirurgiya, 2013, no. 3, pp. 4-21 (in Russ.).
13. Braukhoff M., Machens A., Lorenz K. et al. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B. Novosti mirovoy endokrinnoy khirurgii, 2013, no. 3, pp. 23-25.
14. Scollo C., Baudin E., Travagli J.P. et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab, 2003, 88 (5), pp. 2070-2075 [PubMed].
15. Broekman F., Giovannetti E., Peters G.J. Tyrosine kinase inhibitors: multitargeted or single-targeted? World J. Clin. Oncol, 2011, 2 (2), pp. 80-93 [PMC freearticle] [PubMed].
16. Wells S.A. Jr., Gosnell J.E., Gagel R.F. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol, 2010, 28 (5), pp. 767-772 [PMC free article] [PubMed].